{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T23:32:21Z","timestamp":1788046341263,"version":"build-2784847793"},"reference-count":71,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jgo.2023.101474","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T18:24:08Z","timestamp":1679509448000},"page":"101474","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-na\u00efve metastatic pancreatic cancer - defining a new treatment option for older vulnerable patients"],"prefix":"10.1016","volume":"14","author":[{"given":"Efrat","family":"Dotan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Lenchik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Boutin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helga S.","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Ioffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daneng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne I.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa A.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence Z.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"O'Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgo.2023.101474_bb0005","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.jgo.2023.101474_bb0010","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jgo.2023.101474_bb0015","series-title":"SEER Cancer Statistics Review","year":"1975"},{"key":"10.1016\/j.jgo.2023.101474_bb0020","article-title":"The Next Four Decades: The Older Population in the United States - 2010 to 2050: Population Estimates and Projections","author":"Vincent","year":"2010","journal-title":"U.S. Census Bureau"},{"key":"10.1016\/j.jgo.2023.101474_bb0025","series-title":"American Community Survey 5-Year Estimates","author":"Bureau. USC","year":"2012"},{"issue":"11","key":"10.1016\/j.jgo.2023.101474_bb0030","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"issue":"18","key":"10.1016\/j.jgo.2023.101474_bb0035","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jgo.2023.101474_bb0040","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jgo.2023.101474_bb0045","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jgo.2018.11.001","article-title":"Advanced pancreatic cancer clinical trials: The continued underrepresentation of older patients","volume":"10","author":"White","year":"2019","journal-title":"Journal of Geriatric Oncology"},{"issue":"12","key":"10.1016\/j.jgo.2023.101474_bb0050","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1002\/cam4.1240","article-title":"Nationwide trends in chemotherapy use and survival of elderly patients with metastatic pancreatic cancer","volume":"6","author":"Van Der Geest","year":"2017","journal-title":"Cancer Medicine"},{"issue":"8","key":"10.1016\/j.jgo.2023.101474_bb0055","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1177\/1756283X17713879","article-title":"Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions","volume":"10","author":"Lambert","year":"2017","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.jgo.2023.101474_bb0060","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1186\/1471-2407-14-441","article-title":"FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study","volume":"14","author":"Zaanan","year":"2014","journal-title":"BMC Cancer"},{"issue":"33","key":"10.1016\/j.jgo.2023.101474_bb0065","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.3748\/wjg.v18.i33.4533","article-title":"FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts","volume":"18","author":"Neuzillet","year":"2012","journal-title":"World J Gastroenterol"},{"issue":"10","key":"10.1016\/j.jgo.2023.101474_bb0070","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/sj.bjc.6605374","article-title":"A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer","volume":"101","author":"Yoo","year":"2009","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.jgo.2023.101474_bb0075","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1186\/s12885-016-2798-8","article-title":"Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT)","volume":"16","author":"Vogel","year":"2016","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.jgo.2023.101474_bb0080","doi-asserted-by":"crossref","first-page":"910","DOI":"10.21037\/jgo.2019.06.02","article-title":"First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age","volume":"10","author":"Petrillo","year":"2019","journal-title":"Journal of Gastrointestinal Oncology"},{"issue":"2","key":"10.1016\/j.jgo.2023.101474_bb0085","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/1758834016676011","article-title":"A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis","volume":"9","author":"Ahn","year":"2017","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jgo.2023.101474_bb0090","article-title":"Real world usage of gemcitabine and nabpaclitaxel in older adults with metastatic pancreatic cancer: A single institution experience","volume":"37(4_suppl):358\u2013358","author":"Winer","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1016\/j.jgo.2023.101474_bb0095","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1200\/JCO.18.00089","article-title":"Phase I\/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2","volume":"37","author":"Macarulla","year":"2019","journal-title":"J Clin Oncol"},{"issue":"10018","key":"10.1016\/j.jgo.2023.101474_bb0100","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jgo.2023.101474_bb0105","series-title":"International Society of Geriatric Oncology Annual Conference. Warsaw, Poland","article-title":"Liposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemncitabine-based therapy: data from elderly patients in the pivotal phase 3 NAPOLI-1 study","author":"Mercade","year":"2017"},{"key":"10.1016\/j.jgo.2023.101474_bb0110","article-title":"Dose modifications of liposomal irinotecan (nal-IRI) + 5-fluorouracil\/leucovorin (5-FU\/LV) in NAPOLI-1: Impact on efficacy","volume":"36(4_suppl):388\u2013388","author":"Wang-Gillam","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1016\/j.jgo.2023.101474_bb0115","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jgo.2011.02.003","article-title":"Role of chemotherapy in the very elderly patients with metastatic pancreatic cancer - A Veterans Affairs Cancer Registry analysis","volume":"2","author":"Aldoss","year":"2011","journal-title":"Journal of Geriatric Oncology"},{"issue":"6","key":"10.1016\/j.jgo.2023.101474_bb0120","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jgo.2015.08.001","article-title":"Patterns of care and outcomes of older versus younger patients with metastatic pancreatic cancer: A Fox Chase Cancer Center experience","volume":"6","author":"Vijayvergia","year":"2015","journal-title":"J Geriatr Oncol"},{"issue":"4","key":"10.1016\/j.jgo.2023.101474_bb0125","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/bjc.1993.140","article-title":"Performance status assessment in cancer patients. An inter-observer variability study","volume":"67","author":"Sorensen","year":"1993","journal-title":"Br J Cancer"},{"issue":"25","key":"10.1016\/j.jgo.2023.101474_bb0130","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","article-title":"Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study","volume":"29","author":"Hurria","year":"2011","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.jgo.2023.101474_bb0135","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1200\/JCO.2015.65.4327","article-title":"Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer","volume":"34","author":"Hurria","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.jgo.2023.101474_bb0140","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.2147\/CIA.S57849","article-title":"Optimal management of elderly cancer patients: usefulness of the Comprehensive Geriatric Assessment","author":"Paillaud","year":"2014","journal-title":"Clinical Interventions in Aging"},{"issue":"9","key":"10.1016\/j.jgo.2023.101474_bb0145","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.6004\/jnccn.2021.0043","article-title":"NCCN Guidelines\u00ae Insights: Older Adult Oncology, Version 1.2021","volume":"19","author":"Dotan","year":"2021","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"22","key":"10.1016\/j.jgo.2023.101474_bb0150","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.jgo.2023.101474_bb0155","first-page":"1645","article-title":"Optimal management of elderly cancer patients: usefulness of the Comprehensive Geriatric Assessment","volume":"9","author":"Caillet","year":"2014","journal-title":"Clin Interv Aging"},{"issue":"15_suppl","key":"10.1016\/j.jgo.2023.101474_bb0160","doi-asserted-by":"crossref","first-page":"9065","DOI":"10.1200\/jco.2011.29.15_suppl.9065","article-title":"Prognostic value of multidimensional geriatric assessment (MGA) on survival of a prospective cohort of 880 elderly cancer patients (ECP)","volume":"29","author":"Basso","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"14","key":"10.1016\/j.jgo.2023.101474_bb0165","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.2007.10.6559","article-title":"Comprehensive geriatric assessment for older patients with cancer","volume":"25","author":"Extermann","year":"2007","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jgo.2023.101474_bb0170","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/cncr.21422","article-title":"Developing a cancer-specific geriatric assessment: a feasibility study","volume":"104","author":"Hurria","year":"2005","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.jgo.2023.101474_bb0175","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1200\/JCO.2010.30.6985","article-title":"Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401","volume":"29","author":"Hurria","year":"2011","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jgo.2023.101474_bb0180","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1046\/j.1532-5415.2001.49281.x","article-title":"The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community","volume":"49","author":"Saliba","year":"2001","journal-title":"J Am Geriatr Soc"},{"issue":"8","key":"10.1016\/j.jgo.2023.101474_bb0185","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/annonc\/mdr587","article-title":"Screening older cancer patients: first evaluation of the G-8 geriatric screening tool","volume":"23","author":"Bellera","year":"2012","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.jgo.2023.101474_bb0190","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1002\/cncr.26646","article-title":"Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score","volume":"118","author":"Extermann","year":"2012","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.jgo.2023.101474_bb0195","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/j.1532-5415.2004.52401.x","article-title":"A randomized, controlled trial of comprehensive geriatric assessment and multidisciplinary intervention after discharge of elderly from the emergency department--the DEED II study","volume":"52","author":"Caplan","year":"2004","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jgo.2023.101474_bb0200","first-page":"CD006211","article-title":"Comprehensive geriatric assessment for older adults admitted to hospital","volume":"9","author":"Ellis","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.jgo.2023.101474_bb0205","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.archger.2012.06.012","article-title":"In-home preventive comprehensive geriatric assessment (CGA) reduces mortality--a randomized controlled trial","volume":"55","author":"Frese","year":"2012","journal-title":"Arch Gerontol Geriatr"},{"issue":"9","key":"10.1016\/j.jgo.2023.101474_bb0210","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.6004\/jnccn.2015.0137","article-title":"Geriatric Assessment-Guided Care Processes for Older Adults: A Delphi Consensus of Geriatric Oncology Experts","volume":"13","author":"Mohile","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"10.1016\/j.jgo.2023.101474_bb0215","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.4158","article-title":"Geriatric Assessment-Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer: A Randomized Clinical Trial","volume":"7","author":"Li","year":"2021","journal-title":"JAMA Oncol"},{"issue":"10314","key":"10.1016\/j.jgo.2023.101474_bb0220","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(21)01789-X","article-title":"Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study","volume":"398","author":"Mohile","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jgo.2023.101474_bb0225","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.critrevonc.2010.08.004","article-title":"Influence of geriatric consultation with comprehensive geriatric assessment on final therapeutic decision in elderly cancer patients","volume":"79","author":"Chaibi","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.jgo.2023.101474_bb0230","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1634\/theoncologist.2012-0241","article-title":"Feasibility of computer-based self-administered cancer-specific geriatric assessment in older patients with gastrointestinal malignancy","volume":"18","author":"McCleary","year":"2013","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.jgo.2023.101474_bb0235","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3109\/10428194.2014.953142","article-title":"Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL)","volume":"56","author":"Tucci","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.jgo.2023.101474_bb0240","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1186\/s12885-018-4665-2","article-title":"A multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine +\/\u2212 nab-paclitaxel in elderly pancreatic cancer patients (GrantPax)","volume":"18","author":"Betge","year":"2018","journal-title":"BMC Cancer"},{"issue":"13","key":"10.1016\/j.jgo.2023.101474_bb0245","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1200\/JCO.2015.63.5839","article-title":"Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08\u201302 Study","volume":"34","author":"Corre","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jgo.2023.101474_bb0250","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1200\/JOP.18.00180","article-title":"Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology Summary","volume":"14","author":"Mohile","year":"2018","journal-title":"J Oncol Pract"},{"issue":"3","key":"10.1016\/j.jgo.2023.101474_bb0255","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1634\/theoncologist.5-3-224","article-title":"Management of cancer in the older person: a practical approach","volume":"5","author":"Balducci","year":"2000","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.jgo.2023.101474_bb0260","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.jgo.2023.101474_bb0265","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1200\/JCO.2012.42.9894","article-title":"Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001\u201302 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients","volume":"31","author":"Aparicio","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2023.101474_bb0270","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1080\/13607860500307944","article-title":"Comparative validity of seven scoring systems for the instrumental activities of daily living scale in rural elders","volume":"10","author":"Vittengl","year":"2006","journal-title":"Aging Ment Health"},{"issue":"2","key":"10.1016\/j.jgo.2023.101474_bb0275","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/ageing\/afv202","article-title":"Association between C-reactive protein and physical performance in older populations: results from the International Mobility in Aging Study (IMIAS)","volume":"45","author":"Sousa","year":"2016","journal-title":"Age and Ageing"},{"issue":"6","key":"10.1016\/j.jgo.2023.101474_bb0280","doi-asserted-by":"crossref","first-page":"9723","DOI":"10.1007\/s11357-014-9723-3","article-title":"Interleukin-6 predicts short-term global functional decline in the oldest old: results from the BELFRAIL study","volume":"36","author":"Adriaensen","year":"2014","journal-title":"Age (Dordr)"},{"key":"10.1016\/j.jgo.2023.101474_bb0285","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejca.2015.12.030","article-title":"Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review","volume":"57","author":"Shachar","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jgo.2023.101474_bb0290","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.semcdb.2015.09.001","article-title":"Computed tomography-defined muscle and fat wasting are associated with cancer clinical outcomes","volume":"54","author":"Kazemi-Bajestani","year":"2016","journal-title":"Semin Cell Dev Biol"},{"issue":"15_suppl","key":"10.1016\/j.jgo.2023.101474_bb0295","doi-asserted-by":"crossref","first-page":"11526","DOI":"10.1200\/JCO.2019.37.15_suppl.11526","article-title":"Accelerated sarcopenia and outcomes in older adults with cancer: The Health ABC Study","volume":"37","author":"Williams","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.jgo.2023.101474_bb0300","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ijsu.2017.01.075","article-title":"Clinical impact of sarcopenia on prognosis in pancreatic ductal adenocarcinoma: A retrospective cohort study","volume":"39","author":"Ninomiya","year":"2017","journal-title":"Int J Surg"},{"issue":"5","key":"10.1016\/j.jgo.2023.101474_bb0305","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s11605-018-3695-z","article-title":"Decreased Skeletal Muscle Volume Is a Predictive Factor for Poorer Survival in Patients Undergoing Surgical Resection for Pancreatic Ductal Adenocarcinoma","volume":"22","author":"Sugimoto","year":"2018","journal-title":"J Gastrointest Surg"},{"issue":"10","key":"10.1016\/j.jgo.2023.101474_bb0310","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/gerona\/glz034","article-title":"Approaches to Assessment of Muscle Mass and Myosteatosis on Computed Tomography: A Systematic Review","volume":"74","author":"Amini","year":"2019","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"7","key":"10.1016\/j.jgo.2023.101474_bb0315","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/gerona\/gly183","article-title":"Opportunistic Measurement of Skeletal Muscle Size and Muscle Attenuation on Computed Tomography Predicts 1-Year Mortality in Medicare Patients","volume":"74","author":"Lenchik","year":"2019","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"7","key":"10.1016\/j.jgo.2023.101474_bb0320","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1158\/1055-9965.EPI-16-0133","article-title":"Anticipating the \u201cSilver Tsunami\u201d: Prevalence Trajectories and Comorbidity Burden among Older Cancer Survivors in the United States","volume":"25","author":"Bluethmann","year":"2016","journal-title":"Cancer Epidemiology Biomarkers & Prevention"},{"issue":"24","key":"10.1016\/j.jgo.2023.101474_bb0325","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1200\/JCO.2013.55.0418","article-title":"Designing Therapeutic Clinical Trials for Older and Frail Adults With Cancer: U13 Conference Recommendations","volume":"32","author":"Hurria","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"32","key":"10.1016\/j.jgo.2023.101474_bb0330","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1200\/JCO.2015.63.0319","article-title":"Improving the Evidence Base for Treating Older Adults With Cancer: American Society of Clinical Oncology Statement","volume":"33","author":"Hurria","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.jgo.2023.101474_bb0335","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/EDBK_201133","article-title":"Progress Through Collaboration: An ASCO and U.S. Food and Drug Administration Workshop to Improve the Evidence Base for Treating Older Adults With Cancer","volume":"38","author":"Singh","year":"2018","journal-title":"American Society of Clinical Oncology Educational Book"},{"issue":"12","key":"10.1016\/j.jgo.2023.101474_bb0340","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1056\/NEJMp2106089","article-title":"Treatment of Older Adults with Cancer - Addressing Gaps in Evidence","volume":"385","author":"Bertagnolli","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2023.101474_bb0345","series-title":"Charting a New Course for a System in Crisis","author":"Delivering High-Quality Cancer Care","year":"2013"},{"issue":"9","key":"10.1016\/j.jgo.2023.101474_bb0350","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/bjc.2015.120","article-title":"The impact of comprehensive geriatric assessment interventions on tolerance to chemotherapy in older people","volume":"112","author":"Kalsi","year":"2015","journal-title":"Br J Cancer"},{"issue":"14","key":"10.1016\/j.jgo.2023.101474_bb0355","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1056\/NEJMsa012528","article-title":"Understanding the treatment preferences of seriously ill patients","volume":"346","author":"Fried","year":"2002","journal-title":"N Engl J Med"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406823000711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406823000711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:56:25Z","timestamp":1761818185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406823000711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1879406823000711"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2023.101474","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-na\u00efve metastatic pancreatic cancer - defining a new treatment option for older vulnerable patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2023.101474","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101474"}}